Evaluation of acute urinary retention (AUR) incidence and its predicting factors after onabotulinumtoxinA (iBTXA) initial therapy in patients with idiopathic overactive bladder (OAB).

Trial Profile

Evaluation of acute urinary retention (AUR) incidence and its predicting factors after onabotulinumtoxinA (iBTXA) initial therapy in patients with idiopathic overactive bladder (OAB).

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top